Joe Hsu, MD
Critical Care (Intensivists) · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Hsu’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A85715 · Current
Licensed to practise in California · since 2004 · expires 2028-01-31 · Tufts University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$55,116
Medicare paid this office $55,116 for 96 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 64 | $41,488 | $186 |
| Return visit (30+ min) | 17 | $3,428 | $84 |
| Return visit (30+ min) | 12 | $2,193 | $100 |
Who their Medicare patients are
96 Original Medicare patients in 2024. Average age 69 · Women 51% · Also on Medicaid 29% · Health risk score 2.59. Above the middle of the specialty; the typical critical care (intensivists) clinician is at 2.58.
Conditions among them: High blood pressure 75% · Heart failure 65% · Chronic kidney disease 61% · Atrial fibrillation 56% · Coronary heart disease 55% · COPD 44% · Diabetes 43% · Stroke 31% · Depression 23% · Dementia 16% · Cancer 11%.
The office billed $556,999, Medicare allowed $69,675 and paid $55,116; for 357 services of 16 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 96 | 357 | 69 | 2.59 | $556,999 | $55,116 |
| 2023 | 91 | 430 | 69 | 3.19 | $676,616 | $70,644 |
| 2022 | 105 | 390 | 70 | 2.80 | $607,622 | $64,321 |
| 2021 | 112 | 442 | 68 | 2.20 | $665,357 | $72,183 |
| 2020 | 157 | 547 | 68 | 2.60 | $770,220 | $92,177 |
| 2019 | 163 | 509 | 71 | 2.12 | $619,167 | $80,343 |
| 2018 | 185 | 630 | 71 | 2.35 | $782,527 | $95,538 |
| 2017 | 165 | 493 | 71 | 2.33 | $585,300 | $73,518 |
| 2016 | 144 | 551 | 70 | 2.37 | $617,781 | $78,081 |
| 2015 | 134 | 459 | 69 | 2.42 | $398,308 | $58,348 |
| 2014 | 190 | 690 | 72 | 1.98 | $626,423 | $98,411 |
| 2013 | 142 | 460 | 72 | 2.09 | $399,085 | $65,696 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Critical care, first 30-74 minutes | 67 | $58,391 | $191 |
| Return visit (30+ min) | 17 | $4,286 | $86 |
| Critical care, each additional 30 minutes | 14 | $2,894 | $96 |
2022: 2 services
| Critical care, first 30-74 minutes | 76 | $54,073 | $195 |
| Return visit (30+ min) | 21 | $4,926 | $86 |
2021: 3 services
| Critical care, first 30-74 minutes | 75 | $57,205 | $199 |
| Return visit (30+ min) | 24 | $4,652 | $93 |
| Critical care, each additional 30 minutes | 12 | $3,404 | $100 |
2020: 4 services
| Critical care, first 30-74 minutes | 119 | $78,919 | $201 |
| Critical care, each additional 30 minutes | 26 | $3,456 | $102 |
| Return visit (30+ min) | 18 | $3,249 | $71 |
| Short return visit (20+ min) | 13 | $665 | $48 |
2019: 5 services
| Critical care, first 30-74 minutes | 105 | $67,139 | $198 |
| Return visit (30+ min) | 25 | $3,876 | $68 |
| Long return visit (40+ min) | 12 | $3,433 | $101 |
| Critical care, each additional 30 minutes | 12 | $2,184 | $99 |
| Short return visit (20+ min) | 16 | $789 | $46 |
2018: 3 services
| Critical care, first 30-74 minutes | 118 | $79,652 | $190 |
| Return visit (30+ min) | 34 | $6,013 | $65 |
| Short return visit (20+ min) | 26 | $1,178 | $39 |
2017: 3 services
| Critical care, first 30-74 minutes | 98 | $62,099 | $196 |
| Return visit (30+ min) | 29 | $5,149 | $68 |
| Short return visit (20+ min) | 25 | $1,416 | $42 |
2016: 3 services
| Critical care, first 30-74 minutes | 84 | $65,161 | $196 |
| Short return visit (20+ min) | 23 | $3,385 | $43 |
| Short return visit | 30 | $1,049 | $20 |
2015: 3 services
| Critical care, first 30-74 minutes | 68 | $47,161 | $197 |
| Short return visit (20+ min) | 26 | $3,564 | $43 |
| Short return visit | 35 | $1,681 | $21 |
2014: 3 services
| Critical care, first 30-74 minutes | 120 | $86,984 | $195 |
| Short return visit (20+ min) | 26 | $3,077 | $43 |
| Short return visit | 41 | $2,028 | $22 |
2013: 4 services
| Critical care, first 30-74 minutes | 88 | $58,929 | $191 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $1,885 | $90 |
| Short return visit (20+ min) | 13 | $1,668 | $41 |
| Short return visit | 28 | $1,314 | $21 |
Medicaid work
$3,989 in 2023
Medicaid paid $3,989 for 40 billed services this clinician did in 2023, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 40 | $3,989 |
| 2023 | 40 | 1 | 12 | $3,989 |
| 2021 | 68 | 1 | 13 | $3,936 |
See the largest Medicaid services in earlier years
2021
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 68 | $3,936 |
Drugs they prescribed that Part D paid
$135,037
Pharmacies billed $135,037 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 301) in 2024. At or below the middle of the specialty; the typical critical care (intensivists) clinician is at 0%.
191 generic and fewer than 11 brand-name prescriptions · $135,037 in drug cost · 20 antibiotic prescriptions to 11 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dulera | 17 | $11,304 | $665 |
| Spiriva Handihaler | 12 | $9,868 | $822 |
| Wixela Inhub | 23 | $3,054 | $133 |
| Albuterol Sulfate Hfa | 38 | $834 | $22 |
| Ipratropium | 29 | $602 | $21 |
See all 8 drugs
| Dulera | 17 | $11,304 | $665 |
| Spiriva Handihaler | 12 | $9,868 | $822 |
| Wixela Inhub | 23 | $3,054 | $133 |
| Albuterol Sulfate Hfa | 38 | $834 | $22 |
| Ipratropium | 29 | $602 | $21 |
| Dexamethasone | 18 | $473 | $26 |
| Montelukast | 12 | $225 | $19 |
| Prednisone | 24 | $151 | $6 |
Year by year
| 2024 | 301 | 37 | 0% (0) | None | $135,037 |
| 2023 | 240 | 31 | 0% (0) | None | $35,114 |
| 2022 | 174 | 24 | None | 36% | $221,480 |
| 2021 | 175 | 29 | None | 46% | $148,820 |
| 2020 | 209 | 30 | 0% (0) | 41% | $53,241 |
| 2019 | 301 | 55 | 0% (0) | 45% | $92,614 |
| 2018 | 448 | 64 | 0% (0) | 48% | $93,031 |
| 2017 | 334 | 57 | 0% (0) | 46% | $100,794 |
| 2016 | 354 | 53 | None | 51% | $93,332 |
| 2015 | 417 | 53 | None | 39% | $71,273 |
| 2014 | 500 | 53 | 0% (0) | 37% | $114,238 |
| 2013 | 302 | 39 | 0% (0) | 43% | $68,579 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Symbicort | 15 | $6,559 | $437 |
| Ipratropium | 32 | $1,036 | $32 |
| Albuterol Sulfate Hfa | 29 | $677 | $23 |
| Azithromycin | 13 | $513 | $39 |
| Prednisone | 32 | $435 | $14 |
| Montelukast | 18 | $248 | $14 |
| Sulfamethoxazole-Trimethoprim | 11 | $137 | $12 |
2022: 5 drugs
| Symbicort | 16 | $10,073 | $630 |
| Albuterol Sulfate Hfa | 20 | $785 | $39 |
| Montelukast | 19 | $344 | $18 |
| Prednisone | 27 | $305 | $11 |
| Acyclovir | 11 | $225 | $20 |
2021: 5 drugs
| Spiriva | 17 | $13,041 | $767 |
| Symbicort | 22 | $11,726 | $533 |
| Albuterol Sulfate Hfa | 20 | $988 | $49 |
| Montelukast | 24 | $620 | $26 |
| Acyclovir | 11 | $370 | $34 |
2020: 5 drugs
| Advair Diskus | 18 | $12,660 | $703 |
| Symbicort | 20 | $7,322 | $366 |
| Ipratropium | 14 | $545 | $39 |
| Montelukast | 39 | $390 | $10 |
| Prednisone | 18 | $137 | $8 |
2019: 7 drugs
| Advair Diskus | 27 | $15,419 | $571 |
| Spiriva | 17 | $10,010 | $589 |
| Symbicort | 12 | $5,216 | $435 |
| Ventolin Hfa | 16 | $1,040 | $65 |
| Montelukast | 42 | $688 | $16 |
| Ipratropium | 17 | $583 | $34 |
| Prednisone | 34 | $271 | $8 |
2018: 13 drugs
| Advair Diskus | 65 | $36,365 | $559 |
| Spiriva | 12 | $8,772 | $731 |
| Symbicort | 18 | $6,872 | $382 |
| Incruse Ellipta | 15 | $6,300 | $420 |
| Anoro Ellipta | 14 | $5,617 | $401 |
| Ventolin Hfa | 30 | $2,030 | $68 |
| Proair Hfa | 17 | $1,086 | $64 |
| Azithromycin | 27 | $721 | $27 |
| Ipratropium | 20 | $554 | $28 |
| Montelukast | 41 | $484 | $12 |
| Prednisone | 33 | $304 | $9 |
| Fluticasone Propionate | 30 | $300 | $10 |
| Sulfamethoxazole-Trimethoprim | 12 | $35 | $3 |
2017: 10 drugs
| Advair Diskus | 59 | $31,516 | $534 |
| Spiriva | 19 | $10,989 | $578 |
| Symbicort | 11 | $3,902 | $355 |
| Proair Hfa | 12 | $790 | $66 |
| Ventolin Hfa | 14 | $750 | $54 |
| Ipratropium | 22 | $571 | $26 |
| Azithromycin | 22 | $413 | $19 |
| Montelukast | 28 | $409 | $15 |
| Prednisone | 30 | $360 | $12 |
| Fluticasone Propionate | 15 | $172 | $11 |
2016: 10 drugs
| Advair Diskus | 48 | $27,260 | $568 |
| Spiriva | 38 | $15,613 | $411 |
| Symbicort | 12 | $4,735 | $395 |
| Mycophenolate Mofetil | 13 | $1,461 | $112 |
| Ventolin Hfa | 15 | $1,261 | $84 |
| Azithromycin | 18 | $504 | $28 |
| Montelukast | 29 | $436 | $15 |
| Ipratropium | 13 | $316 | $24 |
| Prednisone | 29 | $289 | $10 |
| Fluticasone Propionate | 15 | $171 | $11 |
2015: 10 drugs
| Advair Diskus | 40 | $23,347 | $584 |
| Spiriva | 53 | $20,527 | $387 |
| Mycophenolate Mofetil | 19 | $2,213 | $116 |
| Proair Hfa | 16 | $786 | $49 |
| Prednisone | 64 | $727 | $11 |
| Fluticasone Propionate | 43 | $720 | $17 |
| Montelukast | 17 | $630 | $37 |
| Azithromycin | 22 | $535 | $24 |
| Pantoprazole | 32 | $416 | $13 |
| Omeprazole | 18 | $173 | $10 |
2014: 11 drugs
| Advair Diskus | 64 | $29,873 | $467 |
| Spiriva | 46 | $18,908 | $411 |
| Mycophenolate Mofetil | 15 | $1,950 | $130 |
| Montelukast | 27 | $1,333 | $49 |
| Prednisone | 71 | $920 | $13 |
| Proair Hfa | 12 | $851 | $71 |
| Fluticasone Propionate | 42 | $757 | $18 |
| Azithromycin | 35 | $672 | $19 |
| Pantoprazole | 37 | $359 | $10 |
| Omeprazole | 18 | $159 | $9 |
| Sulfamethoxazole-Trimethoprim | 12 | $96 | $8 |
2013: 7 drugs
| Advair Diskus | 55 | $20,562 | $374 |
| Spiriva | 19 | $9,705 | $511 |
| Azithromycin | 28 | $1,684 | $60 |
| Montelukast | 13 | $751 | $58 |
| Fluticasone Propionate | 20 | $469 | $23 |
| Pantoprazole | 23 | $297 | $13 |
| Prednisone | 25 | $111 | $4 |
Money from drug and device companies
$213 in 2023
| 2023 | 1 | 4 | None | $213 |
| 2022 | 1 | 1 | None | $37 |
| 2019 | 1 | 2 | None | $219 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Research & Development | None | $213 | 4 payments
|
See all 4 published payments
| Janssen Research & Development | Meals · 2023-02-28 | None | $28 |
| Janssen Research & Development | Meals · 2023-02-28 | None | $32 |
| Janssen Research & Development | Meals · 2023-02-28 | None | $54 |
| Janssen Research & Development | Meals · 2023-02-27 | None | $99 |
See earlier years (2022, 2019)
2022: $37
| Genentech | Esbriet | $37 | 1 payment
|
2019: $219
| Stryker | Hoffmann | $219 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Janssen Research & Development, LLC · Noprodvir0001 · 2023 | Their institution | $312,736 |
| Janssen Research & Development, LLC · Noprodvir0001 · 2024 | Their institution | $164,692 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1609073717
- Licence
- CA A85715California A85715: Current · expires 2028-01-31
- Trained
- Tufts University School of Medicine, 2002
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Internal medicine (207R00000X); Federal specialty code 207RC0200X (207RC0200X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-07-02
- NPI last updated
- 2021-12-28
- NPI record certified
- 2021-12-28
This is when the NPI record was last certified, not a medical board exam.